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– increased plasma levels of BNP in 45.7% of patients, to value 240 ng/ml
increasing cTnI values plasma at 4.34% of cases. 
Biological changes were correlated in most cases with clinical manifesta-
tions, echo changes induced cardiotoxicity and increase of dispersion QT/QTc
intervals. 
Conclusions Increased levels of cardiac biomarkers: BNP and cTnI and of
the dispersion of QT/QTc intervals in children treated with anthracy-
clines±other drugs with cardiotoxic efects positively correlates with installa-
tion of the cardiotoxicity with clinical or infraclinical manifestations,
constituing an useful indicator for the.cardiotoxicity. Changes in this parame-
ters appeared early than echo changes anthracicline induced cardiotoxicity and
is necessary to systematic monitoring these parameters during and after cyto-
static treatment.
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Aims To assess the long-term cardiac prognosis of adults with mitochon-
drial diseases.
Methods and results Between January 2000 and May 2014, we retrospec-
tively included in this study 260 consecutive patients (60% women) ≥18 years
of age, (interquartile range [IQR]; 31 to 54), with genetically proven mito-
chondrial diseases, including 109 with mitochondrial DNA (mtDNA) single
large-scale deletions, 64 with the m.3243A>G mutation in MT-TL1, 51 with
other mtDNA point mutations, and 36 patients with nuclear genes mutations.
Cardiac involvement was present at baseline in 81 patients (30%). Single and
multiple variable analyses were performed in search of predictors of major
adverse cardiac event (MACE), and hazard ratios (HR) and 95% confidence
intervals (CI) were calculated. Over a median follow-up of 7 years [3.6 to
11.7], 27 patients (10%) suffered a MACE, defined as sudden death, death due
to heart failure (HF), resuscitated cardiac arrest, 3rd degree atrioventricular
block, sinus node dysfunction, cardiac transplantation, or hospitalization for
management of HF. Patients with single large-scale mtDNA deletions or
m.3243A>G mutations had the highest incidence of MACE. By multiple vari-
able analysis, intraventricular conduction block (HR=16.9; 95% CI: 7.2 to
39.4), diabetes (HR=7.0; 95% CI: 2.9 to 16.7), premature ventricular com-
plexes (HR=3.6; 95% CI: 1.4 to 9.2) and left ventricular (LV) hypertrophy
(HR=2.5; 95% CI: 1.1 to 5.8) were independent predictors of MACE. In
patients with 0, 1, and ≥2 risk factors, the incidence of MACE was 1.7, 15 and
42% respectively. 
Conclusions Patients with mitochondrial diseases are at high risk of
MACE, independently predicted by intraventricular conduction block, dia-
betes, ventricular prematurity and LV hypertrophy.
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Background Hereditary transthyretin cardiac amyloidosis (mTTR-CA) is a
hypertrophic cardiomyopathy with challenging diagnosis and poor prognosis.
The prevalence of m-TTR in patients with increased left ventricular wall
thickness (LVWT) is unknown.
Methods Prospective and consecutive multicenter study with systematic
genetic screening for mTTR in adult patients with LVWT ≥15mm included in
cardiology primary clinics.
Results 298 patients were genotyped of whom 23% were African descen-
dant. The median (IQR) age was 62(50,74), 74% were men and 36% were in
NYHA class III-IV. The median of maximal LV thickness was 18 (16,
21)mm.17 patients had TTR mutation (5.7%) of whom 15 (5.0) had confirmed
mTTR-CA. All the mTTR-CA were ≥55years meaning that the prevalence of
mTTR-CA was 8.3% above this age. Of the 15 with mTTR-CA, 8 were Afri-
cans and 6 Caucasians. In Africans ≥55 years, the prevalence was 22% and
reached 35% in those over 65 years. The most frequent mutations were V142I
(8), V50M (2) and I127V (2). 
When adjusted to age, neuropathy (OR=20.1; 95%-CI, 5.86-69.4;
P<0.001), carpal tunnel syndrome (OR=15.31; 95%-CI, 4.32-54.3; P<0.001),
ECG low voltage (OR=8.8; 95%-CI, 2.67-29.1; P<0.001), symmetric hyper-
trophy (OR=10.9; 95%-CI, 1.97-59.8; P=0.006), LVEF impairment (OR=10.9;
95%-CI, 1.62-15.5; P=0.005), and late gadolinium enhancement at MRI
(OR=42.9; 95%-CI, 2.38-772; P=0.011) were all associated with increased
odds of CA. 
Conclusions mTTR-CA is frequent in HCM, particularly in African
descendant and patients ≥55 years. mTTR genetic screening may be warranted
for patients with increased LVWT, especially with neuropathy or carpal tunnel
syndrome or LGE at MRI. 
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Friedreich ataxia, due to mitochondrial dysfunction, is the most common
genetic sensory ataxia. It’s due to lack of frataxin. Hypertrophic cardiomyop-
athy is associated with Friedreich ataxia and is the major cause of death,
(80%). 
This study concerned the role of plasma biomarkers, high sensitive tro-
ponin and Nt-proBNP, in the diagnostic of cardiopathy in Friedreich ataxia. 
From December 2012 to January 2015, we included 76 genetically con-
firmed Friedreich’s ataxia patients in Pitié-Salpêtrière Hospital. Clinical exam-
ination, ECG, echocardiography and blood samples were obtained.
Patients were aged of 38±12 years, (mean±sd), 50% were male. 4 patients
had palpitations, 2 dyspnea and no patients had chest pain. 89% had negative
T waves on the ECG. 49% had echographic cardiac hypertrophy according to
Henry’s nomogram. Patients with hypertrophy were younger: 34±10 years
versus 42±14 years, age at onset of the disease was earlier: 15±6 years versus
21±15 years. Interventricular septal wall thickness was 12,9±1,7mm versus
10±1,2mm, and posterior wall thickness was 11,3±1,5mm versus 9,4±1mm.
Left ventricle ejection fraction was similar (64%). For patients with hyper-
trophy, troponin was higher: 22±21 ng/L versus 10±7 ng/L. Plasma Nt-
proBNP was the same between the 2 groups 104±170 ng/L versus 64±122 ng/
L. 5 patients had plasma Nt-proBNP ≥300 ng/L, they all had had atrial fibril-
lation or heart failure.
Plasma High sensitive troponin is a diagnostic marker of hypertrophic car-
diomyopathy in Friedreich ataxia’s patients, whereas plasma Nt-proBNP is
associated with cardiac events and could be a prognostic marker in these
patients.
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